Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1) is designed to systematically collect and document use patterns, effectiveness, and safety of DMARD treatments currently used in the management of rheumatoid arthritis (RA). It is anticipated that study data may help improve the quality of information upon which clinical decisions are based.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborators: Immunex Corporation; Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Antirheumatic Agents

Criteria

Inclusion Criteria:

• Fulfillment of the 1987 American Rheumatism Association criteria for RA

• Currently requiring a new DMARD (change or addition)

Exclusion Criteria:

• Currently enrolled in a clinical trial with treatments or patient visits imposed by a protocol

• Nursing or pregnant women

• Patients with active infection